ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Themes
      • Active ETF
      • Artificial Intelligence
      • Beyond Basic Beta
      • China Insights
      • Climate Insights
      • Core Strategies
      • Crypto
      • Direct Indexing
      • Disruptive Technology
      • Energy Infrastructure
      • ETF Building Blocks
      • ETF Investing
      • ETF Education
      • ETF Strategist
      • Financial Literacy
      • Fixed Income
      • Free Cash Flow
      • Innovative ETFs
      • Institutional Income Strategies
      • Leveraged & Inverse
      • Managed Futures
      • Market Insights
      • Modern Alpha
      • Multifactor
      • Responsible Investing
      • Retirement Income
      • Tax Efficient Income
    • Asset Class
      • Equity
        • U.S. Equity
        • Int'l Developed
        • Emerging Market Equities
      • Alternatives
        • Commodities
        • Gold/Silver/Critical Minerals
        • Currency
        • Volatility
      • Fixed Income
        • Investment Grade Corporates
        • US Treasuries & TIPS
        • High Yield Corporates
        • Int'l Fixed Income
    • ETF Ecosystem
    • ETFs in Canada
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
  • Research
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF of the Week Podcast
    • ETF Prime Podcast
    • Video
  • Company
    • About VettaFi
    • Get VettaFi’ed
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. ETF Building Blocks Channel
  2. SBIO Surges on M&A Announcements
ETF Building Blocks Channel
Share

SBIO Surges on M&A Announcements

Elle CarusoAug 10, 2022
2022-08-10

The ALPS Medical Breakthroughs ETF (SBIO B-) rallied 14.53% last week, propelled by positive earnings and two significant M&A announcements in the portfolio. 

SBIO’s small-to-mid cap holdings have been beaten down year-to-date but, as history suggests, depressed valuations in the space ignited a wave of M&A last week, leading SBIO to outperform its competitors and broader equities markets, ALPS wrote in a recent insight.

SBIO’s rally was led by the news of immunotherapy company, ChemoCentryx Inc. (CCXI, 1.79% weight as of August 5), gaining a scorching 113.89% after Amgen Inc. (AMGN, not in SBIO) announced it would acquire the company for $3.7 billion, or a 115% premium to its prior day close, according to ALPS. The deal highlights CCXI’s immunotherapy portfolio to treat inflammatory diseases and cancer. 

Global Blood Therapeutics Inc. (GBT, 2.07% weight as of August 5) also energized mid-cap biotech last week on reports that the company, which produces a recently-approved immunotherapy for sickle-cell disease, may be acquired by Pfizer Inc. (PFE, not in SBIO) for an estimated $5 billion, or a 118% premium to its prior day close, ALPS wrote.

Cancer-focused company Day One Biopharmaceuticals Inc. (DAWN, 0.73% weight as of August 5) rose 38% last week on earnings that showed expanded development of its immunotherapy to treat solid tumors and relapsed pediatric low-grade glioma. 

Agios Pharmaceuticals Inc. (AGIO, 0.81% weight as of August 5) rose nearly 38% last week after reporting strong launch revenues for its immunotherapy to treat anemia, while Aldeyra Therapeutics Inc. (ALDX, 0.20% weight as of August 5) gained over 37% last week after reporting strong progress on its drug pipeline to treat eye diseases.

Also contributing to SBIO’s increase last week was T-cell immunotherapy company Allovir Inc. (ALVR, 0.25% weight as of August 5), which rose over 69% on strong earnings and data milestones, while Compass Pathways Inc. (CMPS, 0.43% weight as of August 5) increased 28.74% on encouraging progress in using psilocybin to treat depression, ALPS wrote. 

Other biotech ETFs to consider include the SPDR S&P Biotech ETF (XBI A), the iShares Biotechnology ETF (IBB A-), and the First Trust NYSE Arca Biotechnology Index Fund (FBT C+).

For more news, information, and strategy, visit the ETF Building Blocks Channel.

vettafi.com is owned by VettaFi, which also owns the index provider for SBIO. VettaFi is not the sponsor of SBIO, but VettaFi’s affiliate receives an index licensing fee from the ETF sponsor.

Loading Articles...
Our Sites
  • VettaFi
  • Advisor Perspectives
  • ETF Trends
Tools
  • ETF Screener
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Database Pro
More Tools
  • Financial Advisor & RIA Center
Explore ETFs
  • ETF News
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Information
  • Contact Us
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X